ArticleWorld journal of microbiology & biotechnology2025
Combating antimicrobial resistance: a closer look at disrupting Escherichia coli metabolism and motility with biogenic silver nanoparticles.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) poses a dire global threat, with bacterial resistance predicted to cause 10 million deaths annually by 2050 if left unaddressed. Among the leading contributors, Escherichia coli ranks as a critical priority pathogen, driving the need for innovative strategies to combat resistance. This study addresses the urgent demand by exploring the antibacterial efficacy and mode of action of biogenic silver nanoparticles (AgNPs) synthesized using Emblica officinalis. AgNPs, characterized as spherical (average size: 46.5 nm) with high stability (zeta potential: -39.02 mV) and photoluminescent properties, exhibited potent antimicrobial activity, with minimum inhibitory concentrations ranging from 9.76 to 19.53 ppm. RNA-seq analysis revealed substantial metabolic and regulatory shifts in E. coli upon AgNP exposure, including upregulation of arginine biosynthesis, metabolism, and transport genes (e.g., argC, argB, argA, artJ), which supported ATP production via the Arginine Deiminase (ADI) pathway and enhanced stress resilience through polyamine synthesis. Upregulation of carA showed the interconnectedness of arginine and pyrimidine biosynthesis under energy-depleted conditions. Simultaneously, downregulation of motility-related genes (flhDC, fliC) disrupted flagellar biosynthesis, rendering E. coli non-motile and more vulnerable to oxidative stress. This was linked to reduced cAMP-CRP complex activity and arginine-sodium competition at flagellar motors. Structural analyses confirmed a face-centered cubic crystalline structure and functionalization with biomolecules, enhancing biocompatibility. Cytotoxicity assays on MDA-MB-231 cells demonstrated dose-dependent reductions in cell viability, with manageable safety profiles. These findings highlight biogenic AgNPs as eco-friendly, effective antimicrobial agents exploiting bacterial metabolic disruption and impaired motility to counter resistance, offering promising solutions to mitigate the AMR crisis.
Indexed as
Identifiers
40560274What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.